63619-82-9

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 63619-81-8 1-(4-methoxybenzoyl)-2-tetralone 
• 4181-97-9 phenyl 4-methoxybenzoate 
• 106-93-4 ethylene dibromide 

Downstream Products

• 63619-83-0 3-(4-methoxyphenyl)-4-(4-hydroxybenzoyl)-1,2-dihydronaphthalene 

Relevant academic research and scientific papers

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods for treating resistant tumors

The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

Methods of treating nueropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein. Another embodiment of this invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

NAPHTHYL BRADYKININ RECEPTOR ANTAGONISTS

This invention provides methods of treating a physiological disorder associated with an excess of bradykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.

Naphthyl tachykinin receptor antagonists to treat physiological conditions

This invention provides methods of treating a physiological disorder associated with an excess of tachykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.

Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl) ethoxy]-phenyl]methanone, methanesulfonic acid salt

Acylation of the sodio anion of β-tetralone with phenyl anisoate, followed by a Grignard reaction of the resultant 4 with 4-methoxyphenylmagnesium bromide, gave rise to two novel dihydronaphthalene isomers 5 and 6. Regioselective demethylation of either 5 or 6 by NaSEt produced [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl](4-hydroxyphenyl)methanone (7). Etherification of the phenolic group of 6duced [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl](4-hydroxyphenyl)methanone (7). Etherification of the phenolic group of 7 by N-(2-chloroethyl)pyrrolidine and subsequent methanesulfonate salt formation provided [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, methane sulfonic acid salt. Potent antiestrogenic activity of 3 was demonstrated by both oral and subcutaneous administration to rats and mice. In vitro binding studies with rat uterine cystosol estrogen receptors indicate compound 3 has a very high binding affinity which exceeds that of estradiol.